Impact of mast cells in systemic lupus erythematosus: can inflammation be inhibited?
cytokines
inflammation
IL-37
mast cell
systemic lupus erythematosus
Journal
Journal of biological regulators and homeostatic agents
ISSN: 0393-974X
Titre abrégé: J Biol Regul Homeost Agents
Pays: Italy
ID NLM: 8809253
Informations de publication
Date de publication:
Historique:
entrez:
15
6
2019
pubmed:
15
6
2019
medline:
9
8
2019
Statut:
ppublish
Résumé
Systemic lupus erythematosus (SLE), is a complex chronic inflammatory autoimmune disease, with rheumatological manifestations, which afflicts mainly women. SLE presents various heterogeneous clinical aspects and different pathogeneses and involves the production of anti- DNA autoantibodies which are deposited as immune complexes in various organs and tissues, provoking inflammation. These diseases cause multiple tissue and organ damage in arthritis, skin lesions, hematologic changes, renal and neurologic disorders, and others (Table I). In SLE, serum contains anti-nucleus antibodies and anti-DNA antibodies that can be important biomarkers for patients suffering from this disease.
Substances chimiques
Antibodies, Antinuclear
0
Biomarkers
0
Types de publication
Editorial
Langues
eng
Pagination
669-673Informations de copyright
Copyright 2019 Biolife Sas www.biolifesas.org.